Related Experiment Video

Updated: May 20, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

PI3 kinase inhibitors in the clinic: an update

Jean-Emmanuel Kurtz1, Isabelle Ray-Coquard

  • 1Department of Oncology and Hematology, Hôpitaux Universitaires de Strasbourg, 1 Av Molière, 67098 Strasbourg, France. j-emmanuel.kurtz@chru-strasbourg.fr

Anticancer Research
|July 4, 2012
PubMed

Insights

The phosphoinositide-3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway regulates cell growth. This review covers PI3K biology and its inhibitors, highlighting novel drugs in clinical trials for cancer therapy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • The PI3K/AKT/mTOR pathway is crucial for cellular functions including growth, metabolism, and translation.
  • Proteins in this pathway are key targets for anticancer drug development, with mTOR inhibitors already in clinical use.
  • Advances in understanding PI3K structure and function have enabled the creation of novel inhibitors with improved safety profiles.

Purpose of the Study:

  • To review the fundamental biology of PI3K.
  • To focus on PI3K inhibitors currently undergoing clinical investigation.
  • To discuss future directions and novel clinical trials for PI3K inhibition in cancer therapy.

Main Methods:

  • Literature review of PI3K biology.
  • Analysis of current clinical trial data for PI3K inhibitors.
  • Discussion of emerging research and future therapeutic strategies.

Main Results:

  • The PI3K/AKT/mTOR pathway plays a vital role in cancer cell proliferation and survival.
  • Novel PI3K inhibitors demonstrate potential for improved efficacy and reduced toxicity compared to earlier agents.
  • Several PI3K inhibitors are progressing through clinical trials, showing promise for various malignancies.

Conclusions:

  • Targeting the PI3K pathway remains a significant strategy in oncology.
  • Ongoing research and clinical trials are essential for optimizing PI3K-targeted therapies.
  • Future directions include developing more selective inhibitors and combination therapies to overcome resistance and enhance treatment outcomes.

More Related Videos

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...